Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When Size Matters: Advanced Treatment of Acute Pulmonary Embolism Caused by a Large Snake-Like Thrombus.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation.

Med (New York, N.Y.)·2026
Same author

Clinical, Metabolic, and Virological Insights into Hepatitis C Virus-Infected Patients through the Combinatorial Metabolic Dysfunction-associated Steatotic Liver Disease Framework: Evidence from an Italian Cohort.

Journal of gastrointestinal and liver diseases : JGLD·2026
Same author

Safety of Invasive Procedures During Adult Extracorporeal Membrane Oxygenation: A Systematic Review.

Journal of clinical medicine·2026
Same author

Orthohantavirus Infection Mimicking Acute Viral Hepatitis: An Underrecognized Clinical Presentation.

Pathogens (Basel, Switzerland)·2026
Same author

Evaluating Sycophancy in Frontier Models Using Persona-Driven Challenge.

medRxiv : the preprint server for health sciences·2026
Same journal

A Response to the Letter to the Editor: Population-informed Assessment of Clonality in Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Is Less Actually More? Precision Is the Key!

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

A Response to the Letter to the Editor: Supporting a Neuroprotective Effect of Lorlatinib Across ALK and ROS1 Targets.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Leveraging Vulnerabilities of Molecular Subtypes to Identify Rational Combination Therapies-The Next Wave in Extensive-Stage SCLC?

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

"Hiding in Plain Sight: The Neuro-Protective Benefit of Tropomyosin Receptor Kinase Inhibition in Non-Neurotrophic Receptor Tyrosine Kinase-Driven Lung Cancers": Supporting a Neuroprotective Effect of Lorlatinib Across ALK and ROS1 Targets.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

TTF-1-Negative Lung Adenocarcinoma: An Aggressive Subtype Refractory to Immunotherapy and KRAS<sup>G12C</sup> Inhibition.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2026

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
11:20

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

11.5K

Molecular Profiling Across 80,000 Patients With Lung Cancer.

Alessandro Russo1, Manana Javey2, Richard S P Huang3

  • 1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Medical Oncology Department, Humanitas Istituto Clinico Catanese, Misterbianco, Catania, Italy.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|March 28, 2026
PubMed
Summary
This summary is machine-generated.

Actionable genomic alterations are prevalent across most Non-Small Cell Lung Cancer (NSCLC) subtypes, supporting universal biomarker testing for all patients. This ensures equitable access to targeted therapies for improved outcomes.

Keywords:
Biomarker testingCGPEthnicityNSCLCSarcomatoidSquamous cell carcinoma

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

517

Related Experiment Videos

Last Updated: Jun 22, 2026

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
11:20

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

11.5K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

517

Area of Science:

  • Oncology
  • Genomics
  • Molecular Diagnostics

Background:

  • Biomarker testing is crucial for Non-Small Cell Lung Cancer (NSCLC) treatment selection.
  • Despite guidelines, many advanced NSCLC patients do not receive precision oncology due to testing disparities.
  • This study investigates actionable genomic alteration distribution across NSCLC subtypes.

Purpose of the Study:

  • To analyze the prevalence of actionable genomic alterations in NSCLC across various histologic subtypes and demographic groups.
  • To support universal molecular testing for all NSCLC patients to ensure equitable access to targeted therapies.

Main Methods:

  • Retrospective analysis of 82,328 NSCLC cases tested with comprehensive genomic profiling (CGP) via next-generation sequencing (NGS).
  • Histologic subtypes were confirmed by Board Certified Anatomic Pathologists.
  • Data collected between 2014-2022.

Main Results:

  • Actionable genomic alterations were found in 35.1% of NSCLC cases.
  • Lung adenocarcinoma (LUAD) and adenosquamous (ASC) had higher rates of actionable alterations (45.8%, 40.9%) compared to other histologies.
  • Specific alterations like METex14 skipping mutations were more frequent in sarcomatoid histology (9.95%).
  • Tumor mutation burden (TMB) varied by histology, with higher rates in large cell (LCC) and not otherwise specified (NOS).
  • Actionable alterations were generally associated with low TMB (80.88%).
  • Correlations were observed between age and specific mutations/rearrangements (BRAF/ERBB2, ALK/RET/ROS1, MET).
  • EGFR mutations and KRAS G12C were more common in females.
  • EGFR alterations showed a strong correlation with South/East Asian and American ancestry.

Conclusions:

  • This large-scale analysis confirms significant biomarker prevalence across diverse NSCLC histologies.
  • The findings support comprehensive biomarker workup for all NSCLC patients.
  • Ensuring universal testing can improve access to precision therapies for a broader patient population.